Univest
Univest
  • Markets

Nifty Pharma Prediction for Tomorrow, 23 July 2026: Index Falls 1.31 Percent to 25,751.15 as Dr Reddy’s Leads Losses

  • July 22, 2026
  • Posted by: Ankit Jaiswal
  • Category: News
No Comments
Nifty Pharma Prediction for Tomorrow, 23 July 2026
 

Nifty Pharma prediction for tomorrow 23 July 2026: index at 25,751.15, down 1.31 percent on Wednesday, reversing its two-session rebound. Support 25,545. Resistance 25,935.

Nifty pharma prediction for tomorrow: Nifty Pharma closed at 25,751.15 on Wednesday, down 341.70 points or 1.31 percent, reversing its own two-session rebound from earlier this week, with Dr Reddy’s Laboratories falling 1.92 percent among the notable stock-specific declines. This nifty pharma prediction for tomorrow is built on Friday, 10 July 2026’s closing data, the last completed session before markets reopen on Monday, 13 July 2026.

Kunal Singla, Associate Director at Univest, notes that the Nifty Pharma prediction for tomorrow reflects a genuinely surprising reversal, since the sector’s own decline came precisely as FMCG rallied sharply the same session, suggesting Wednesday’s severe escalation triggered a more selective market reaction than a simple flight to all defensives uniformly.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Market Recap Behind the Nifty pharma prediction for tomorrow
  • Nifty pharma prediction for tomorrow: Trend and Key Levels
  • A Selective Reaction, Not a Uniform Defensive Rotation
  • Key Triggers in the Nifty pharma prediction for tomorrow
  • Stocks to Watch in the Pharma Sector
  • Risks to the Nifty pharma prediction for tomorrow
  • Conclusion
  • FAQs on the Nifty pharma prediction for tomorrow
    • What is the Nifty Pharma prediction for tomorrow, 23 July 2026?
    • Which analyst gave the Nifty Pharma prediction for tomorrow?
    • Why did pharma fall while FMCG rallied on the same day?
    • Which stock drove pharma’s decline on Wednesday?

Market Recap Behind the Nifty pharma prediction for tomorrow

The index opened at 25,935.45, touched a high of 25,935.45 and a low of 25,545.60 before closing at 25,751.15, falling through the session. Dr Reddy’s Laboratories fell 1.92 percent to Rs 1,182.80, a notable stock-specific decline that dragged the broader index lower alongside the day’s genuinely severe broader market selloff.

Nifty pharma prediction for tomorrow: Trend and Key Levels

Trend: Bearish Below 25,935

Level Type Value
Support 1 25,545
Support 2 25,350
Resistance 1 25,935
Resistance 2 26,110

Kunal Singla flags 25,545 as the key support, with 25,935 as the near-term resistance, matching Wednesday’s open. A close above 26,110 would suggest the sector’s earlier rebound has resumed, while a break under 25,350 would confirm Wednesday’s reversal has genuine downside momentum.

A Selective Reaction, Not a Uniform Defensive Rotation

The US carried out its 11th straight night of strikes against Iran, while Iranian drones struck oil facilities in neighbouring Kuwait and Iran retaliated by targeting sites in Bahrain, Kuwait and Jordan. Critically, Saudi crude’s alternate shipping route through the Bab el-Mandeb Strait is now itself under threat of blockade by Iran’s Houthi allies, leaving no clearly safe route. Brent crossed 92 dollars a barrel, a five-week high, and India VIX jumped 5.63 percent to 13.31, a genuine fear spike. Nifty Auto was the session’s lone major sectoral gainer. Kunal Singla notes that pharma’s own decline, even as FMCG rallied sharply the same session, suggests Wednesday’s severe escalation triggered a more selective market reaction than a simple flight to all defensives, with stock-specific factors like Dr Reddy’s own weakness also playing a genuine role.

Key Triggers in the Nifty pharma prediction for tomorrow

These triggers dominate the outlook heading into Monday, 13 July 2026:

  • Whether pharma’s reversal extends: A further decline Thursday would confirm this is more than a single-day pullback.
  • Dr Reddy’s own specific weakness: Worth tracking for whether it’s an isolated stock-specific issue or reflects broader sector concerns.
  • HDFC Bank fell a further 1.09 percent to Rs 753.15 on Wednesday, its third straight decline, now down roughly 8 percent cumulatively since Friday’s close.

Talk to a SEBI Registered Investment Advisor Before Your Next Trade

Stocks to Watch in the Pharma Sector

Key pharma constituents worth tracking alongside the broader sector outlook.

Sun Pharma: Sun Pharma is a sector bellwether worth tracking for stock-level signals within the pharma space.

Nifty FMCG: Nifty FMCG rose 0.80 percent the same session, a genuine divergence among defensives worth noting.

Risks to the Nifty pharma prediction for tomorrow

These factors can invalidate this outlook:

  • Continued sector-specific weakness: If Dr Reddy’s own decline reflects broader concerns, it could weigh on the sector further.
  • US regulatory news: Any adverse FDA or pricing decision would be a clear sector-specific negative.
  • A deeper reversal: Would suggest Tuesday’s own rebound was more fragile than initially appeared.

Download the Univest iOS App or Univest Android App to track live Nifty Pharma levels and get daily research from SEBI registered analysts.

Conclusion

The Nifty Pharma prediction for tomorrow, 23 July 2026, is bearish below 25,935, after the sector reversed its own two-session gains sharply even as FMCG rallied the same session. Kunal Singla flags 25,545 as the key support in the Nifty Pharma prediction for tomorrow, with Dr Reddy’s own trajectory worth watching heading into Thursday.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on the Nifty pharma prediction for tomorrow

What is the Nifty Pharma prediction for tomorrow, 23 July 2026?

Ans. The Nifty Pharma prediction for tomorrow, 23 July 2026, is bearish below 25,935. The index closed at 25,751.15 on Wednesday, down 1.31 percent, reversing its own two-session rebound.

Which analyst gave the Nifty Pharma prediction for tomorrow?

Ans. Kunal Singla, Associate Director at Univest, has shared the Nifty Pharma prediction for tomorrow, flagging 25,545 as the key support level.

Why did pharma fall while FMCG rallied on the same day?

Ans. Both sectors are typically considered defensives, yet pharma fell 1.31 percent while FMCG rose 0.80 percent on Wednesday, a divergence the Nifty Pharma prediction for tomorrow attributes to Dr Reddy’s own stock-specific weakness alongside a more selective, rather than uniform, defensive rotation pattern.

Which stock drove pharma’s decline on Wednesday?

Ans. Dr Reddy’s Laboratories fell 1.92 percent to Rs 1,182.80 on Wednesday, a notable stock-specific decline the Nifty Pharma prediction for tomorrow flags as worth tracking for whether it’s isolated or reflects broader sector concerns.



News
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply